Multiple sclerosis (MS) is an inflammatory-demyelinating disease of the central nervous system (CNS). Treatment options have been changing during the last two decades with novel emerging agents acting at different levels of the immune system. These drugs proved effective
in preventing relapses and disability progression. Natalizumab (NAT) and fingolimod (FTY720) are the most widely used agents when first-
line drugs therapy fail to control disease activity in relapsing remitting (RR) MS patients. FTY720 exerts an action upon the immune system not yet fully understood but it may be associated with an immunological
dysregulation leading to an imbalance of T-cells within the CNS. TY720 is a sphingosine 1-phosphate receptor modulator that binds to lymphocytes preventing their egress from peripheral lymphoid
tissues into the blood stream. FTY720 is the first oral drug approved for the treatment of RRMS and significantly reduces relapse rate, lesion
accumulation and disability progression in these patients.
Last date updated on December, 2020